Cytomegalovirus and other infectious issues related to face transplantation: Specific considerations, lessons learned, and future recommendations

Plastic and Reconstructive Surgery

Volumn 127, Issue 4, 2011, Pages 1515-1523

  Gordon, Chad R ^a,b,c   Avery, Robin K ^a,b,c   Abouhassan, William ^a,b,c   Siemionow, Maria ^a,b,c  

^a Institute of Dermatology and Plastic Surgery   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ALLOTRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; FACIAL TRANSPLANTATION; HUMAN; INFECTION; OPPORTUNISTIC INFECTION; RISK FACTOR; VIREMIA;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FACIAL TRANSPLANTATION; HUMANS; INFECTION; OPPORTUNISTIC INFECTIONS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIREMIA;

EID: 79955017196     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318208d03c     Document Type: Article

References (59)

1. Gordon CR. Composite tissue allografts: Should we reconsider the terminology? Plast Reconstr Surg. 2009;124:464e-465e.
2. Gordon CR, Siemionow M, Zins J. Composite tissue allotransplantation: A proposed classification system based on relative complexity. Transplant Proc. 2009;41:481-484.
3. Siemionow MZ, Kulahci Y, Bozkurt M. Composite tissue allotransplantation. Plast Reconstr Surg. 2009;124: e327-e339.
4. American Society of Transplantation Infectious Disease Community of Practice. Guidelines for the management and prevention of infectious complications after solid organ transplantation. Am J Transplant. 2009;9: S1-S257.
5. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751. (Pubitemid 28268592)
6. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601-2614. (Pubitemid 350294226)
7. Siemionow M, Gordon CR. Overview of guidelines for establishing a face transplant program: A work in progress. Am J Transplant. 2010;10:1290-1296.
8. Siemionow MZ, Gordon CR. Institutional review board-based recommendations for medical institutions pursuing protocol approval for face transplantation. Plast Reconstr Surg. 2010;126:1232-1239.
9. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis. 2009;11:195-202.
10. Snydman DR. Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis. Clin Infect Dis. 2005;40:709-712. (Pubitemid 40381345)
11. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect. 2007;13:953-963. (Pubitemid 47382250)
12. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant. 2004;4:928-936. (Pubitemid 38745592)
13. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6:2134-2143. (Pubitemid 44199547)
14. Schneeberger S, Lucchina S, Lanzetta M, et al. Cytomegalovirus-related complications in human hand transplantation. Transplantation 2005;80:441-447. (Pubitemid 41209410)
15. Bonatti H, Brandacher G, Margreiter R, Schneeberger S. Infectious complications in three double hand recipients: Experience from a single center. Transplant Proc. 2009;41:517-520.
16. Boriskin YS, Booth JC, Corbishley CM, et al. Human cytomegalovirus and acute rejection after heart transplantation are not directly associated. J Med Virol. 1996;50:59-70. (Pubitemid 26348944)
17. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Häyry PJ, Lemström KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis. 1999;1:115-126.
18. Kobayashi H, Kobayashi M, McCauley RL, Herndon DN, Pollard RB, Suzuki F. Cadaveric skin allograft-associated cytomegalovirus transmission in a mouse model of thermal injury. Clin Immunol. 1999;92:181-187. (Pubitemid 29362548)
19. Gordon CR, Zor F, Siemionow M. Skin area quantification in preparation for concomitant upper extremity and face transplantation: A cadaver study and literature review. Transplantation (in press).
20. Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl Int. 2009;22:1031-1040.
21. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005;79:85-90. (Pubitemid 40140005)
22. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol. 2006;16:281-287. (Pubitemid 44497309)
23. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097. (Pubitemid 34289682)
24. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989;261:3607-3609.
25. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620. (Pubitemid 38523584)
26. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Metaanalysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870-880. (Pubitemid 46202222)
27. Coffman KL, Gordon C, Siemionow M. Psychological outcomes with face transplantation: Overview and case report. Curr Opin Organ Transplant. 2010;15:236-240.
28. Paradis C, Siemionow M, Papay F, et al. Ethical considerations in the first American face transplant. Plast Reconstr Surg. 2010;126:308-315.
29. Gordon CR, Siemionow M, Papay F, et al. The world's experience with facial transplantation: What have we learned thus far? Ann Plast Surg. 2009;63:572-578.
30. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defense by cytomegalovirus: Timing is everything. J Intern Med. 2010;267:483-501.
31. Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis. 2008;40:71-75. (Pubitemid 350192309)
32. Eid AJ, Brown RA, Arthurs SK, et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4 (+) and CD8 (+) T cells in kidney allograft recipients at risk of CMV infection. Transpl Int. 2010;23:506-513.
33. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med. 2010;152:761-679.
34. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six month prophylaxis is cost-effective in transplant patients at high risk of cytomegalovirus infection. J Am Soc Nephrol. 2009;20:2449-2458.
35. Siemionow M, Papay F, Alam D, et al. First U. S. near-total human face transplantation: A paradigm shift for massive facial injuries. Lancet 2009;374:203-209.
36. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant. 2003;3:731-735. (Pubitemid 36745246)
37. Lantieri L, Meningaud JP, Grimbert P, et al. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: A 1-year follow-up study. Lancet 2008;372:639-645.
38. Siemionow MZ, Papay F, Djohan R, et al. First U. S. near-total human face transplantation: A paradigm shift for massive complex injuries. Plast Reconstr Surg. 2010;125:111-122.
39. Painter W, Mossad S, Siemionow M, et al. First use of CMX001, a novel antiviral drug, for the suppression of cytomegalovirus infection in solid organ transplant patients: A case series. Oral late-breaking abstract presentation at: American Transplant Congress 2010; May 1-5, 2010; San Diego, Calif.
40. Riddle DJ, Dubberke ER. Clostridium difficileinfection in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13:592-600.
41. Boeke CE, Pauly ME, Hatch-Stock H, Jackson JB. CMV antibody prevalence and seroincidence in plateletpheresis donors. J Clin Apher. 2008;23:63-65. (Pubitemid 351656256)
42. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis. 2002;39:1088-1095. (Pubitemid 34454229)
43. Gordon CR, Siemionow M, Coffman K, et al. The Cleveland Clinic FACES score: A preliminary assessment tool for identifyingthe optimal face transplant candidate. J Craniofac Surg. 2009;20:1969-1974.
44. Gordon CR, Siemionow M. Requirements for establishing a hand transplant program. Ann Plast Surg. 2009;63:262-273.
45. Devauchelle B, Badet L, Lengele B, et al. First human face allograft: Early report. Lancet 2006;368:203-209. (Pubitemid 44037773)
46. Dubernard JM, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med. 2007;357:2451-2460. (Pubitemid 350272784)
47. Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: A 2-year follow-up study. Lancet 2008;372:631-638.
48. Meningaud JP, Benjoar MD, Hivelin M, Hermeziu O, Toure G, Lantieri L. The procurement of total human face graft for allotransplantation: A preclinical study and the first clinical case. Plast Reconstr Surg. 2010;126:1181-1190.
49. Danzinger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2009;9: S258-S262.
50. Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis. 2009;49:710-716.
51. Singh N, Lortholary O, Alexander BD, et al. Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005;80:1131-1133. (Pubitemid 41611940)
52. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003;37:221-229. (Pubitemid 36930353)
53. Avery RK, Michaels MG. Strategies for safe living following solid organ transplantation. Am J Transplant. 2009;9: S252-S257.
54. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant. 2007;21:309-313. (Pubitemid 46711391)
55. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711-721.
56. Siemionow M, Klimczak A. Tolerance and future directions for composite tissue allograft transplants: Part II. Plast Reconstr Surg. 2009;123:7e-17e.
57. Strong C. An ongoing issue concerning facial transplantation. Am J Transplant. 2010;10:1115-1116.
58. Kotton CN, Hibberd PL; AST Infectious Diseases Community of Practice. Travel medicine and the solid organ transplant recipient. Am J Transplant. 2009;9(Suppl 4): S273-S281.
59. Lanzetta M, Petruzzo P, Dubernard JM, et al. Second report (1998-2006) of the International Registry of Hand and Composite Tissue Transplantation. Transpl Immunol. 2007;18:1-6. (Pubitemid 46929078)